Clinical trials: Schizophrenia, Undifferentiated
Paranoid Schizophrenia, Schizophrenia
MK0557 for the Treatment of Cognitive Impairment in Patients With Schizophrenia (0557-027)
The purpose of this study is to determine the safety and effectiveness of an investigational drug for the treatment of cognitive impairment in patients with schizophrenia.
- Trial name
- NCT00482430
- Testing
- MK0557
- Volunteers
- 50 people
- Sponsor
- Merck Sharp & Dohme LLC
Schizophrenia
Study Of Talnetant Versus Placebo And Risperidone In Schizophrenia
This study will evaluate whether talnetant (200mg, 400mg, 600mg) twice a day is effective compared to placebo and risperidone 1-3mg twice a day in treating the positive and negative symptoms of schizophrenia.
- Trial name
- NCT00103727
- Testing
- Talnetant, risperidone
- Where
- 22 sites in United States
- Volunteers
- 282 people
- Sponsor
- GlaxoSmithKline
Schizophrenia, Paranoid, Schizophrenia, Disorganized
Flexible Dose, Long-term Safety Study of Asenapine for the Treatment of Schizophrenia in Adolescents (P05897)
This study is designed to evaluate whether asenapine, which is approved by the United States Food and Drug Administration (US FDA) for acute treatment of schizophrenia in adults, is generally safe and well tolerated in…
- Conditions
- Schizophrenia, Paranoid, Schizophrenia, Disorganized, Schizophrenia, Undifferentiated
- Trial name
- NCT01190267
- Testing
- asenapine
- Volunteers
- 204 people
- Sponsor
- Organon and Co
Schizophrenia
Transcutaneous Non-invasive Vagus Nerve Stimulation (t-VNS) in the Treatment of Schizophrenia
Randomized, controlled, double-blind, two-armed clinical investigation to show the efficacy and safety of transcutaneous vagus nerve stimulation (t-VNS), applied at the left auricle, in schizophrenia.
- Trial name
- 02VNS2009 (NCT01176721)
- Testing
- t-VNS verum
- Where
- 2 sites in Germany
- Volunteers
- 20 people
- Sponsor
- cerbomed GmbH
Schizophrenia, Paranoid, Schizophrenia, Disorganized
Fixed Dose Efficacy and Safety Study of Asenapine for the Treatment of Schizophrenia in Adolescents (P05896)
This study is designed to evaluate whether asenapine, which is approved by the United States Food and Drug Administration (US FDA) for acute treatment of schizophrenia in adults, is also effective in adolescents with…
- Conditions
- Schizophrenia, Paranoid, Schizophrenia, Disorganized, Schizophrenia, Undifferentiated
- Trial name
- NCT01190254
- Testing
- asenapine 2.5 mg, asenapine 5.0 mg
- Volunteers
- 306 people
- Sponsor
- Organon and Co
Paranoid Schizophrenia
MK0249 for the Treatment of Cognitive Impairment in Patients With Schizophrenia (0249-016)
The purpose of this study is to determine the safety and effectiveness of an investigational drug MK0249 for the treatment of the cognitive impairment in patients with schizophrenia.
- Trial name
- NCT00506077
- Testing
- MK0249
- Volunteers
- 55 people
- Sponsor
- Merck Sharp & Dohme LLC